Tag: tapimmune

April 25, 2017

Q BioMed Announces Licensing Agreement for Development of Drug to Treat Rare Pediatric Disorder

Q BioMed Inc. (OTCQB: QBIO) and ASDERA LLC today announce a licensing agreement that provides Q BioMed with the worldwide...
February 7, 2017

TapImmune Expands Intellectual Property On PolyStart™ Platform For Use In Next-Generation T-Cell Vaccines

TapImmune, Inc. (NASDAQ:TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment...
January 24, 2017

TapImmune Announces Progress In Its Phase 2 Ovarian Cancer Clinical Trial

TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment...
January 10, 2017

TapImmune Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients

TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for...
January 3, 2017

Top Biotech Trends for 2017

No doubt about it—2016 was a tumultuous year for biotech. But that doesn’t mean you should be afraid of this...
December 6, 2016

Investing in Immuno-Oncology: A Q&A with TapImmune's John Bonfiglio

TapImmune CEO, Dr. John Bonfiglio, on the immuno-oncology market, plus what you should keep in mind when comparing immuno-oncology companies.
November 1, 2016

TapImmune Announces Commercialization Pathway For Its HER2neu Vaccine

TapImmune, clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of...